SCHEMBL3758060

SCHEMBL3758060

Cc1cc2nccn2c(C)c1Br

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.37
CDK8 P49336 2/20 0.37
ROCK1 Q13464 2/20 0.37
FLT1 P17948 1/20 0.37
CDK9 P50750 1/20 0.37
LIMK1 P53667 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37
IDO1 P14902 1/20 0.36
CHRM4 P08173 2/20 0.33
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
CHEK1 O14757 1/20 0.30
MAP4K4 O95819 1/20 0.30
CSF1R P07333 1/20 0.30
PRKACA P17612 1/20 0.30
KDR P35968 1/20 0.30
MAP2K1 Q02750 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17815907 0.84 CDK8 (0.39) L3MBTL1CDK8ROCK1FLT1CDK9
SCHEMBL17812872 0.74 FLT1 (0.35) CDK8ROCK1FLT1CDK9LIMK1
SCHEMBL3767439 0.73 KDM4E (0.36) CDK8ROCK1FLT1CDK9LIMK1
SCHEMBL3754494 0.72 ALDH1A1 (0.39) CDK8ROCK1FLT1CDK9LIMK1
SCHEMBL5572841 0.71 CDK8 (0.41) L3MBTL1CDK8ROCK1FLT1CDK9
SCHEMBL2673260 0.71 L3MBTL1 (0.34) L3MBTL1CDK8ROCK1FLT1CDK9
SCHEMBL17174248 0.69 CDK8 (0.47) CDK8ROCK1FLT1CDK9LIMK1
SCHEMBL10276341 0.69 ADORA2A (0.35) L3MBTL1CDK8ROCK1FLT1CDK9
SCHEMBL15743345 0.67 HPGDS (0.36) CDK8ROCK1FLT1CDK9LIMK1
SCHEMBL23811383 0.67 L3MBTL1 (0.42) L3MBTL1IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014080241-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF Piramal Enterprises Limited (IN) 2014-05-30 WO disclosed
US-20100298366-A1 CHEMOKINE RECEPTOR BINDING COMPOUNDS GENZYME CORPORATION (US) 2010-11-25 US disclosed
US-7790747-B2 Chemokine receptor binding compounds GENZYME CORPORATION (US) 2010-09-07 US disclosed
US-20090099205-A1 Chemokine receptor binding compounds GENZYME CORPORATION 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298366-A1 CHEMOKINE RECEPTOR BINDING COMPOUNDS CCR5, CXCR3, CCL5 L3MBTL1 3659/4885CDK8 1135/4885ROCK1 1223/4885
US-20090099205-A1 Chemokine receptor binding compounds CCR5, CXCR3, CCL5 L3MBTL1 3659/4885CDK8 1135/4885ROCK1 1223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.